Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma

被引：6

作者：

Couronne, Thomas ^{[1
]}

Girot, Paul ^{[2
]}

Hadoux, Julien ^{[3
]}

Lecomte, Thierry ^{[4
]}

Durand, Alice ^{[1
]}

Fine, Caroline ^{[1
]}

Vandevoorde, Katia ^{[1
]}

Lombard-Bohas, Catherine ^{[1
]}

Walter, Thomas ^{[1
]}

机构：

[1] Hosp Civils Lyon, Serv Oncol Med, Hop Edouard Herriot, Lyon, France

[2] Ctr Hosp Dept Vendee, Serv Gastroenterol & Oncol Digest, La Roche Sur Yon, France

[3] Inst Gustave Roussy, Serv Med Nucl & Cancerol Endocrinienne, Villejuif, France

[4] Ctr Hosp Reg Univ Tours, Serv Hepatogastroenterol & Cancerol Digest, Tours, France

来源：

ENDOCRINE CONNECTIONS | 2020年 / 9卷 / 06期

关键词：

dacarbazine; temozolomide; alkylating agents; neuroendocrine carcinoma; neuroendocrine tumours; COMBINATION; TUMORS; CHEMOTHERAPY; SURVIVAL; FAILURE; REGIMEN; FOLFIRI; G3;

D O I：

10.1530/EC-20-0192

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: First-line chemotherapy in metastatic neuroendocrine carcinomas (NECs) is based on etoposide and platinum. However, there is no standard concerning second-line treatment. The objective of this study was to evaluate efficacy and tolerance of dacarbazine or temozolomide in metastatic digestive NEC as post first-line treatment. Material and methods: This study included patients with a metastatic NEC of digestive or unknown primary site. All patients received platinum-etoposide as first-line chemotherapy. Primary endpoint was progression-free survival (PFS). Secondary endpoints were clinical/morphological responses, toxicity, and overall survival (OS). Results: Twenty-seven patients were included: 17 received dacarbazine and 10 temozolomide as post-first line treatments. Median PFS was 3.0 (95%CI (2.2;3.7)) months. There was no significant difference between dacarbazine and temozolomide on PFS. Clinical and morphological responses were found in 12 and 9 patients, respectively. Median OS was 7.2 (95%CI (2.2;12.2)) months. The toxicity profile was that expected with such treatments. Conclusion: LV5FU2-dacarbazine or temozolomide-capecitabine chemotherapies allow a temporary clinical response for almost half of patients and/or a morphological response for a third of patients.

引用

页码：498 / 505

页数：8

共 19 条

[1] Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study [J].

Campana, Davide ;

Walter, Thomas ;

Pusceddu, Sara ;

Gelsomino, Fabio ;

Graillot, Emmanuelle ;

Prinzi, Natalie ;

Spallanzani, Andrea ;

Fiorentino, Michelangelo ;

Barritault, Marc ;

Dall'Olio, Filippo ;

Brighi, Nicole ;

Biasco, Guido .

ENDOCRINE, 2018, 60 (03) :490-498

[2] Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses [J].

de Mestier, Louis ;

Walter, Thomas ;

Brixi, Hedia ;

Evrard, Camille ;

Legoux, Jean-Louis ;

de Boissieu, Paul ;

Hentic, Olivia ;

Cros, Jerome ;

Hammel, Pascal ;

Tougeron, David ;

Lombard-Bohas, Catherine ;

Rebours, Vinciane ;

Ruszniewski, Philippe ;

Cadiot, Guillaume .

NEUROENDOCRINOLOGY, 2019, 108 (04) :343-353

[3] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[4] ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas [J].

Garcia-Carbonero, R. ;

Sorbye, H. ;

Baudin, E. ;

Raymond, E. ;

Wiedenmann, B. ;

Niederle, B. ;

Sedlackova, E. ;

Toumpanakis, C. ;

Anlauf, M. ;

Cwikla, J. B. ;

Caplin, M. ;

O'Toole, D. ;

Perren, A. .

NEUROENDOCRINOLOGY, 2016, 103 (02) :186-194

[5] Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma [J].

Hadoux, J. ;

Malka, D. ;

Planchard, D. ;

Scoazec, J. Y. ;

Caramella, C. ;

Guigay, J. ;

Boige, V. ;

Leboulleux, S. ;

Burtin, P. ;

Berdelou, A. ;

Loriot, Y. ;

Duvillard, P. ;

Chougnet, C. N. ;

Deandreis, D. ;

Schlumberger, M. ;

Borget, I. ;

Ducreux, M. ;

Baudin, E. .

[6] Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms [J].

Heetfeld, M. ;

Chougnet, C. N. ;

Olsen, I. H. ;

Rinke, A. ;

Borbath, I. ;

Crespo, G. ;

Barriuso, J. ;

Pavel, M. ;

O'Toole, D. ;

Walter, T. .

[7] FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3 [J].

Hentic, O. ;

Hammel, P. ;

Couvelard, A. ;

Rebours, V. ;

Zappa, M. ;

Palazzo, M. ;

Maire, F. ;

Goujon, G. ;

Gillet, A. ;

Levy, P. ;

Ruszniewski, P. .

[8] Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry [J].

Korse, Catharina M. ;

Taal, Babs G. ;

van Velthuysen, Marie-Louise F. ;

Visser, Otto .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (08) :1975-1983

[9] O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET) [J].

Lemelin, Annie ;

Barritault, Marc ;

Hervieu, Valerie ;

Payen, Lea ;

Peron, Julien ;

Couvelard, Anne ;

Cros, Jerome ;

Scoazec, Jean-Yves ;

Bin, Sylvie ;

Villeneuve, Laurent ;

Lombard-Bohas, Catherine ;

Walter, Thomas .

DIGESTIVE AND LIVER DISEASE, 2019, 51 (04) :595-599

[10] Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas [J].

Olsen, Ingrid H. ;

Sorensen, Jens B. ;

Federspiel, Birgitte ;

Kjaer, Andreas ;

Hansen, Carsten P. ;

Knigge, Ulrich ;

Langer, Seppo W. .

SCIENTIFIC WORLD JOURNAL, 2012,

← 1 2 →